Drug intelligence / Profile preview

kevacumab

Development stage: Preclinical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

Kevacumab is an anti-C5 antibody, a type of C5 complement inhibitor, used in the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). It works by targeting and inhibiting the C5 protein of the complement system, which plays a crucial role in the pathogenesis of PNH.

Targets

Beyond the preview

Go deeper on kevacumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on kevacumab.

Explore the full profile